Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Amalus Therapeutics logo — precisely remodeling tissues. profoundly reshaping lives.

Amalus Therapeutics

precisely remodeling tissues. profoundly reshaping lives.

Founded 2023 Belgium Belgium 3 employees Convertible Note Total: $500.00K Biotechnology, Health Care

General Information

Company Name Amalus Therapeutics
Founded Year 2023
Location Belgium Belgium
Employees 3
Industries Biotechnology, Health Care
Funding Stage Convertible Note
Social

BounceWatch is an independent company data service, not affiliated with Amalus Therapeutics. To contact Amalus Therapeutics, visit amalustherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Amalus Therapeutics compare?

A PDF of Amalus Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Amalus Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Amalus Therapeutics

Amalus Therapeutics is a biotechnology startup based in Belgium, founded in 2023. The company's slogan, "precisely remodeling tissues. profoundly reshaping lives.", reflects its core focus on leveraging selective fibroblast modulation to develop transformative therapeutics. By targeting pathologically activated fibroblasts with unparalleled selectivity, Amalus Therapeutics aims to achieve precise tissue remodeling and normalization, offering multiple therapeutic benefits across Biotechnology and Health Care sectors. In August 2023, the company secured a €500.00K Convertible Note investment from BioInnovation Institute, emphasizing the confidence of investors in Amalus Therapeutics' innovative approach to addressing diseases driven by abnormal tissue structure. The investment signifies a notable endorsement of the company's potential to make a significant impact in the biotechnology and healthcare industries. Amalus Therapeutics' pioneering technology and strategic partnerships position it as a promising player in the space, offering potential for substantial growth and disruptive contributions to medical advancements.

Business keywords: tissue remodeling, fibroblast modulation, therapeutics, disease-associated fibroblasts, selective, precise, normalization, technology, pathological activation, diseases, transformative, precision medicine

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note €500.00K 1
BioInnovation Institute
BioInnovation Institute
31 Aug 2023

Amalus Therapeutics Alternatives & Competitors

View All Alternatives
Amalus Therapeutics vs
Modalis Therapeutics
Modalis Therapeutics United States

Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology

IPO
23 employees
Biotechnology, Health Care
Amalus Therapeutics vs
Vera Therapeutics, Inc.
Vera Therapeutics, Inc. United States

We are a clinical-stage biotechnology company developing treatments that transform patients’ lives.

Post-IPO Equity
349 employees
Biotechnology, Health Care
Amalus Therapeutics vs
Biosplice Therapeutics
Biosplice Therapeutics United States

Restore health by delivering first-in-class therapies that harness alternative splicing

Grant
37 employees
Biotechnology, Health Care
View all alternatives

FAQ About Amalus Therapeutics

precisely remodeling tissues. profoundly reshaping lives.
Amalus Therapeutics was founded in 2023.
Amalus Therapeutics is headquartered in Belgium.
Amalus Therapeutics operates in Biotechnology and Health Care. Its work centres on tissue remodeling, fibroblast modulation, therapeutics and disease-associated fibroblasts.
Amalus Therapeutics has approximately 3 employees.
Amalus Therapeutics has completed 1 funding round, raising a total of $500.00K. The latest funding stage is Convertible Note.
Top alternatives and competitors to Amalus Therapeutics include Modalis Therapeutics, Vera Therapeutics, Inc., Biosplice Therapeutics, Promedior, Q32 Bio Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Amalus Therapeutics and Modalis Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Amalus Therapeutics, https://bouncewatch.com/company/amalus-therapeutics, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout